Gender-related differences in pharmacokinetics and their clinical significance

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 5, 1999, Pages 339-346

  Tanaka, E ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMITRIPTYLINE; CARBAMAZEPINE; CHLORZOXAZONE; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DAPSONE; DIAZEPAM; DIGOXIN; ERYTHROMYCIN; IMIPRAMINE; ISONIAZID; LIDOCAINE; MEPHENYTOIN; METHYLPHENOBARBITAL; MIDAZOLAM; NAPROXEN; PARACETAMOL; PHENYTOIN; PROPRANOLOL; STEROID HORMONE; THEOPHYLLINE; TIOTIXENE; TOLBUTAMIDE; TRIAZOLAM; WARFARIN;

ALCOHOL CONSUMPTION; CIGARETTE SMOKING; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENDER; HORMONAL REGULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MENOPAUSE; MENSTRUATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PREGNANCY; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; ISOENZYMES; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREGNANCY; SEX CHARACTERISTICS;

EID: 0032731634     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00246.x     Document Type: Review

References (91)

1. 1. Giudicelli JF, Tillement JP. (1977) Influence of sex on drug kinetics in man. Clinical Pharmacokinetics, 2, 157-166.
2. 2. Wilson K. (1984) Sex-related differences in drug disposition in man. Clinical Pharmacokinetics, 9, 189-202.
3. 3. Bonate PL. (1991) Gender-related differences in xenobiotic metabolism. Journal of Clinical Pharmacology, 31, 684-690.
4. 4. Harris RZ, Benet LZ, Schwartz JB. (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs, 50, 222-239.
5. 5. Xie CX, Piecoro LT, Wermeling DP. (1997) Gender-related considerations in clinical pharmacology and drug therapeutics. Critical Care Nursing Clinics of North America, 9, 459-468.
6. 6. Kashuba AD, Nafziger AN. (1998) Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clinical Pharmacokinetics, 34, 203-218.
7. 7. Back DJ, Orme ML. (1990) Pharmacokinetic drug interactions with oral contraceptives. Clinical Pharmacokinetics, 18, 472-484.
8. 8. Lou YC. (1990) Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metabolism Reviews, 22, 451-475.
9. 9. Meyer UA, Zanger UM, Grant D, Blum M. (1990) Genetic polymorphisms of drug metabolism. Advances in Drug Research, 19, 197-241.
10. 10. Meyer UA. (1990) Molecular genetics and the future of pharmacogenetics. Pharmacology and Therapeutics, 46, 349-355.
11. 11. Loft S, Poulsen HE. (1990) Prediction of xenobiotic metabolism by non-invasive methods. Pharmacology and Toxicology, 67, 101-108.
12. 12. Watkins PB. (1990) Role of cytochrome P450 in drug metabolism and hepatotoxicity. Seminars in Liver Disease, 10, 235-250.
13. 13. Wood AJJ, Zhou HH. (1991) Ethnic differences in drug disposition and responsiveness. Clinical Pharmacokinetics, 20, 350-373.
14. 14. Cholerton S, Daly AK, Idle JR. (1992) The role of individual human cytochrome P450 in drug metabolism and clinical response. Trends in Pharmacological Sciences, 13, 434-439.
15. 15. Soucek P, Gut I. (1992) Cytochrome P-450 in rat: structures, functions, properties and relevant human forms. Xenobiotica, 22, 83-103.
16. 16. Wrighton SA, Stevens JC. (1992) The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.
17. 17. Gonzalez FJ, Idle JR. (1994) Pharmacogenetic phenotyping and genotyping. Clinical Pharmacokinetics, 26, 59-70.
18. 18. Watokins PB. (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171-184.
19. 19. Bertolsson L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Clinical Pharmacokinetics, 29, 192-209.
20. 20. Jalan R, Hayes PC. (1995) Review article: quantitative tests of liver function. Alimentary Pharmacology and Therapeutics, 9, 263-270.
21. 21. Meyer UA. (1996) Overview of enzymes of drug metabolism. Journal of Pharmacokinetics and Biopharmaceutics, 24, 449-459.
22. 22. Wrighton SA, Branden MV, Ring BJ. (1996) The human drug metabolizing cytochrome P450. Journal of Pharmacokinetics and Biopharmaceutics, 24, 461-473.
23. 23. Wilkinson GR. (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475-490.
24. 24. Eichelbaum M, Evert B. (1996) Influence of pharmacogenetics on drug disposition and response. Clinical and Experimental Pharmacology and Physiology, 23, 983-985.
25. 25. Echelbaum M, Evert B. (1996) Influence of pharmacogenetics on drug disposition and response. Clinical and Experimental Pharmacology and Physiology, 23, 983-985.
26. 26. Linder MW, Prough RA, Valdes R. (1997) Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clinical Chemistry, 43, 254-266.
27. 27. Nakamura K, Goto F, Ray WA, et al. (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clinical Pharmacology and Therapeutics, 38, 402-408.
28. 28. Wilkinson GR, Guengerich FP, Branch RA. (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacology and Therapeutics, 43, 53-76.
29. 29. Bertilsson L, Lou YQ, Du YL, et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
30. 30. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. (1993) Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin hydroxylation. Archives of Biochemistry and Biophysics, 306, 240-245.
31. 31. Mehgoub A, Dring LG, Idle JR, Lancaster R, Smith RL. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet, 2, 584-586.
32. 32. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16, 183-187.
33. 33. Brøsen K, Gram LF. (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 36, 537-547.
34. 34. Meyer UA, Skoda RC, Zanger UM. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: molecular mechanisms. Pharmacology and Therapeutics, 46, 297-308.
35. 35. Eichelbaum M, Gross AS. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacology and Therapeutics, 46, 377-394.
36. 36. Lennard MS. (1990) Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacology and Toxicology, 67, 273-283.
37. 37. Gonzalez FK, Meyer UA. (1991) Molecular genetics of the debrisoquine/sparteine metabolism. Clinical Pharmacology and Therapeutics, 50, 233-238.
38. 38. Kupfer A, Schmidt B, Preisig R, Pfaff G. (1984) Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet, 2, 517-518.
39. 39. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197-204.
40. 40. Marinac JS, Foxworth JW, Willsie SK. (1995) Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects. Therapeutic Drug Monitoring, 17, 120-124.
41. 41. Guengerich FP. (1989) Characterization of human microsomal cytochrome P-450 enzymes. Annual Review of Pharmacology and Toxicology, 29, 241-264.
42. 42. Gonzalez FJ, Gelboin HV. (1991) Human cytochromes P450: evolution, catalytic activities and interindividual variations in expression. Progress in Clinical and Biological Research, 372, 11-20.
43. 43. Relling MV, Lin JS, Ayers GD, Evans WE. (1992) Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clinical Pharmacology and Therapeutics, 52, 643-658.
44. 44. Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW. (1991) Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. Journal of Clinical Psychopharmacology, 11, 296-301.
45. 45. Nafziger AN, Bertino JS Jr. (1989) Sex-related differences in theophylline pharmacokinetics. European Journal of Clinical Pharmacology, 37, 97-100.
46. 46. Cuzzolin L, Schinella M, Tellini U, Pezzoli L, Lippi U, Benoni G. (1990) The effect of sex and cardiac failure on the pharmacokinetics of a slow-release theophylline formulation in the elderly. Pharmacological Research, 22(Suppl. 1), 137-138.
47. 47. Jennings TS, Nafziger AN, Davidson L, Bertino JS Jr. (1993) Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. Journal of Laboratory and Clinical Medicine, 122, 208-216.
48. 48. Rugstad HE, Hundal O, Holme I, Herland OB, Husby G, Giercksky KE. (1986) Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clinical Rheumatology, 5, 389-398.
49. 49. Sherwin AL, Loynd JS, Bock GW, Sokolowski CD. (1974) Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels. Epilepsia, 15, 507-521.
50. 50. Travers RD, Reynolds EH, Gallagher BB. (1972) Variation in response to anticonvulsants in a group of epileptic patients. Archives of Neurology, 27, 29-33.
51. 51. Houghton GW, Richens A, Leighton M. (1975) Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. British Journal of Clinical Pharmacology, 2, 251-256.
52. 52. Tanaka E. (1999) Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. Journal of Clinical Pharmacy and Therapeutics, 24, 7-16.
53. 53. Tanaka E. (1999) Clinically significant pharmacokinetic drug interactions with benzodiazepines. Journal of Clinical Pharmacy and Therapeutics, 24, 347-355.
54. 54. Hooper WD, Qing MS. (1990) The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clinical Pharmacology and Therapeutics, 48, 633-640.
55. 55. Leemann TD, Transon C, Bonnabry P, Dayer P. (1993) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Under Experimental and Clinical Research, 19, 189-195.
56. 56. Richardson CJ, Blocka KL, Ross SG, Verbeeck RK. (1985) Effects of age and sex on piroxicam disposition. Clinical Pharmacology and Therapeutics, 37, 13-18.
57. 57. May DG, Porter J, Wilkinson GR, Branch RA. (1994) Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clinical Pharmacology and Therapeutics, 55, 492-500.
58. 58. Abernethy DR, Greenblatt DJ, Shader RI. (1985) Imipramine and desipramine disposition in the elderly. Journal of Pharmacology and Experimental Therapeutics, 232, 183-188.
59. 59. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone G. (1990) Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clinical Pharmacokinetics, 19, 241-255.
60. 60. Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. (1985) Biologic determinants of propranolol disposition: results from 1308 patients in the beta-blocker heart attack trial. Clinical Pharmacology and Therapeutics, 38, 509-518.
61. 61. Walle T, Walle UK, Cowart TD, Conradi EC. (1989) Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clinical Pharmacology and Therapeutics, 46, 257-263.
62. 62. Gilmore DA, Gal J, Gerber JC, Nies AS. (1992) Age and gender influence the stereoselective pharmacokinetics of propranolol. Journal of Pharmacology and Experimental Therapeutics, 261, 1181-1186.
63. 63. Walle T, Walle K, Mathur RS, Palesch YY, Conradi EC. (1994) Propranolol metabolism in normal subjects: association with sex steroid hormones. Clinical Pharmacology and Therapeutics, 56, 127-132.
64. 64. Koop DR. (1992) Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal, 6, 724-730.
65. 65. Sato A, Nakajima T, Fujiwara Y, Murayama N. (1975) Kinetic studies on sex difference in susceptibility to chronic benzene intoxication - with special reference to body fat content. British Journal of Industrial Medicine, 32, 321-328.
66. 66. Kim RB, O'Shea D, Wilkinson GR. (1996) Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clinical Pharmacology and Therapeutics, 57, 645-655.
67. 67. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. (1986) Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clinical Pharmacology and Therapeutics, 40, 438-443.
68. 68. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. (1991) Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clinical Pharmacology and Therapeutics, 50, 404-409.
69. 69. Wilkinson GR. (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475-490.
70. 70. Sitar DS, Duke PC, Benthuysen JL, Sanford TJ, Smith NT. (1989) Ageing and alfentanil disposition in healthy volunteers and surgical patients. Canadian Journal of Anaesthesia, 36, 149-154.
71. 71. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. (1977) Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anaesthesiology, 87, 26-35.
72. 72. Kashuba AD, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN. (1998) Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clinical Pharmacology and Therapeutics, 64, 269-277.
73. 73. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MT, Van Buren CT. (1986) Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radio-immunoassay. Transplantation, 41, 459-464.
74. 74. Holazo AA, Winkler MB, Patel IH. (1988) Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. Journal of Clinical Pharmacology, 28, 1040-1045.
75. 75. Austin KL, Mather LE, Philpot CR, McDonald PJ. (1980) Intersubject and dose-related variability after intravenous administration of erythromycin. British Journal of Clinical Pharmacology, 10, 273-279.
76. 76. Watkins PB, Turgeon DK, Saenger P, et al. (1992) Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clinical Pharmacology and Therapeutics, 52, 265-273.
77. 77. Hulst LK, Fleishaker JC, Peters CR, Harry JD, Wright DM, Ward P. (1994) Effect of age and gender on tirilazad pharmacokinetics in humans. Clinical Pharmacology and Therapeutics, 55, 378-384.
78. 78. Meffin PJ, Brooks PM, Sallustio BC. (1984) Alterations in prednisolone disposition as a result of time of administration, gender and dose. British Journal of Clinical Pharmacology, 17, 395-404.
79. 79. Lew KH, Ludwig EA, Milad MA, et al. (1993) Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics, 54, 402-414.
80. 80. Miners JO, Attwood J, Birkett DJ. (1983) Influence of sex and oral contraceptive steroids on paracetamol metabolism. British Journal of Clinical Pharmacology, 16, 503-509.
81. 81. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. (1982) Obesity, sex, and acetaminophen disposition. Clinical Pharmacology and Therapeutics, 31, 783-790.
82. 82. Divoll M, Abernethy DR, Ameer B, Greenblatt DJ. (1982) Acetaminophen kinetics in the elderly. Clinical Pharmacology and Therapeutics, 31, 151-156.
83. 83. Yukawa E, Mine H, Higuchi S, Aoyama T. (1992) Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Journal of Pharmacy and Pharmacology, 44, 761-765.
84. 84. Miners JO, Robson RA, Birkett DJ. (1984) Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. British Journal of Clinical Pharmacology, 18, 240-243.
85. 85. Greenblatt DJ, Abernethy DR, Matlis R, Harmatz JS, Shader RI. (1984) Absorption and disposition of ibuprofen in the elderly. Arthritis and Rheumatism, 27, 1066-1069.
86. 86. Hakkola A, Tanaka E, Pelkonen O. (1998) Developmental expression of cytochrome P450 enzymes in human liver. Pharmacology and Toxicology, 82, 209-217.
87. 87. Tanaka E. (1998) In vivo age-related changes in hepatic drug-oxidizing capacity in humans. Journal of Clinical Pharmacy and Therapeutics, 23, 247-256.
88. 88. George J, Byth K, Farrell GC. (1995) Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochemical Pharmacology, 50, 727-730.
89. 89. Hunt CM, Westerkam WR, Stave GM. (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochemical Pharmacology, 44, 275-283.
90. 90. Shapiro BH, Agrawal AK, Pampori NA. (1995) Gender differences in drug metabolism regulated by growth hormone. International Journal of Biochemistry and Cell Biology, 27, 9-20.
91. 91. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-243.